JMJD2D depletion results in reduced cell proliferation.

Abstract

<p>(<b>A</b>) HCT116 cells expressing control or JMJD2D shRNA were treated with 1 µM adriamycin or with DMSO as a control for 24 h. Downregulation of JMJD2D was assessed by Western blotting; immunoblotting for actin served as a loading control. (<b>B</b>) Wild-type or p53^−/− HCT116 cells were challenged with control or JMJD2D shRNA (#1 or #3) and then treated without or with 1 µM adriamycin for 72 h. The number of cells were counted and presented as percent of the control shRNA for each wild-type and p53^−/− HCT116 cells. Statistical significance of differences between various experimental conditions is indicated in the graph.</p